Tango Therapeutics, Inc.
TNGX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.54 | -0.16 | -0.09 | -0.57 |
| FCF Yield | -6.56% | -27.63% | -10.95% | -4.01% |
| EV / EBITDA | -14.70 | -3.09 | -7.52 | -25.42 |
| Quality | ||||
| ROIC | -20.46% | -17.65% | -14.59% | -10.37% |
| Gross Margin | 80.35% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -1.95 | 0.94 | 1.05 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.03% | -10.33% | 18.13% | 19.17% |
| Free Cash Flow Growth | 11.03% | -13.54% | -9.75% | -40.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 0.51 | 0.82 | 0.48 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -375.41 | 0.00 | 0.00 | 0.00 |